Study demonstrating, Cardium’s Gene Activated Matrix or GAM technology accelerates periodontal tissue regeneration of oral implant-supporting wounds, was published in the scientific journal, Gene Therapy.
According to Cardium, the preclinical study demonstrate that AdPDGF-B/collagen is safe, accelerates and enhances oral implant osseointegration, and leads to bone-implant contact, defect fill, bone area and tissue mineral density than placebo.
The preclinical study demonstrated that the initial response to a bolus administration of rhPDGF-BB protein was strong, but the short half-life of the protein results in rapid degradation with a decrease in the mitogenic response. In contrast, PDGF-B gene delivery using Cardium’s Gene Activated Matrix technology resulted in sustained protein expression that lasted for approximately 14 days. The benefits of this prolonged availability are expected to be more evident in planned large animal critical size defect models, the company reported.
The study also reported that there was no dissemination of the AdPDGF-B vector away from the treatment site, and no alteration of hematological and clinical chemistry parameters associated with the AdPDGF-B/collagen treatments.
The authors scientific journal, Gene Therapy, said: “This approach shows the ability of Ad-PDGF-B to accelerate oral implant osseointegration. The data support the concept that Ad-PDGF-B gene delivery may be an effective and safe mode of therapy comparable with PDGF-BB application to promote dental implant osseointegration and oral bone repair.”